Clinical characteristics and treatment of penetrating aortic ulcer
-
摘要:
目的 分析并总结主动脉穿透性溃疡(penetration aortic ulcer,PAU)患者的临床特点及治疗方法的选择。 方法 回顾性分析2016年1月—2019年11月蚌埠医学院第一附属医院血管外科收治的32例PAU患者的临床资料,其中保守治疗组12例,主动脉腔内修复(endovascular aneurysm repair,EVAR)组20例,对2组患者的临床特点及治疗效果进行分析。 结果 EVAR组患者住院时间较保守治疗组短、入院时D-二聚体水平较保守治疗组高(均P<0.05),EVAR组患者溃疡直径、溃疡深度及并发主动脉壁内血肿(intramural hematoma,IMH)与保守治疗组相比较,差异有统计学意义(均P<0.05),其他方面差异均无统计学意义(均P>0.05)。近期随访中保守治疗组患者新发主动脉夹层的发生率高于EVAR组,差异有统计学意义(P<0.05),中远期随访中2组间溃疡增大、新发主动脉夹层的发生率EVAR组均略低于保守治疗组,但差异无统计学意义(P=0.089、0.089),其他指标相比差异均无统计学意义(均P>0.05)。 结论 EVAR治疗PAU是一种安全、有效的方法,与保守治疗相比较,可降低近期主动脉夹层发生率。对于持续性疼痛症状、合并IMH以及有主动脉破裂征象的患者建议积极行EVAR治疗。 Abstract:Objective To analyse and summarise the clinical characteristics of patients with penetrating aortic ulcer (PAU) and the choice of treatment. Methods Clinical data of 32 PAU patients admitted to the Vascular Surgery Department of the First Affiliated Hospital of Bengbu Medical College from January 2016 to November 2019 were retrospectively analysed, including 12 cases in the conservative treatment group and 20 cases in the endovascular aneurysm repair (EVAR) group. The clinical characteristics and therapeutic effects of the two groups were analysed. Results The hospital time of the patients in the EVAR group was short compared with the conservative treatment group (all P < 0.05). The D-dimer level, ulcer diameter, depth of the ulcer and concurrent aortic intramural hematoma (intramural hematoma, IMH) of the EVAR group were higher compared with those of the conservative treatment group, and the differences were statistically significant (all P < 0.05). No statistically significant differences were observed in the other areas (all P>0.05). Recent follow-up on new conservative treatment group patients showed that the incidence of aortic dissection was higher than that in the EVAR group, and the difference was statistically significant (P < 0.05). Long-term follow-up showed that the risk of ulcer increases for the two groups. The incidence of new aortic dissection for the EVAR group was slightly lower than that for the conservative treatment group, but there was no statistically significant difference (P=0.089, 0.089). Other indicators had no statistically significant differences (all P>0.05). Conclusion EVAR is a safe and effective method in the treatment of PAU as it can reduce the incidence of recent aortic dissection compared with the conservative treatment. EVAR is recommended for patients with persistent pain symptoms, combined IMH and signs of aortic rupture. -
表 1 2组PAU患者临床资料对比[例(%)]
组别 例数 性别(男/女,例) 年龄(x±s,岁) 吸烟史 既往病史 临床症状 高血压病 冠心病 糖尿病 肾脏疾病 胸痛 背痛 腹痛 无症状 保守治疗组 12 7/5 69.67±12.64 2(16.7) 9(75.0) 2(16.7) 1(8.3) 2(16.7) 8(66.7) 6(50.0) 1(8.3) 3(25.0) EVAR组 20 17/3 66.35±11.95 8(40.0) 16(80.0) 2(10.0) 2(10.0) 2(10.0) 15(75.0) 8(40.0) 3(15.0) 2(10.0) t值 0.745 P值 0.116a 0.462a 0.248a 0.999a 0.620a 0.999a 0.620a 0.696a 0.718a 0.999a 0.338a 组别 例数 收缩压(x±s,mm Hg) 舒张压(x±s,mm Hg) 甘油三酯(x±s,mmol/L) 总胆固醇(x±s,mmol/L) D-二聚体(x±s,mg/L) 住院天数(x±s,d) 医疗费用(x±s,元) 保守治疗组 12 154.58±18.53 90.17±11.14 2.31±2.64 3.92±1.00 0.81±0.70 24.25±5.38 18 592.96±7 008.06 EVAR组 20 153.75±27.25 87.50±14.00 1.63±0.87 4.26±1.16 3.73±5.64 19.60±6.52 129 036.77±42 740.81 t值 0.093 0.561 0.865 0.843 2.286 2.079 11.306 P值 0.926 0.579 0.404 0.406 0.033 0.046 < 0.001 注:a为采用Fisher精确检验。 表 2 2组PAU患者影像学资料对比[例(%)]
组别 例数 主动脉弓部溃疡 降主动脉溃疡 腹主动脉溃疡 胸腔积液 并发IMH 溃疡直径(x±s,mm) 溃疡深度(x±s,mm) 主动脉弓参考直径(x±s,mm) 保守治疗组 12 0(0.0) 10(83.3) 2(16.7) 2(16.7) 2(16.7) 12.17±3.35 8.58±1.38 28.33±2.15 EVAR组 20 2(10.0) 15(75.0) 3(15.0) 2(10.0) 14(70.0) 18.90±10.13 14.30±6.71 28.60±1.64 t值 2.733 3.685 0.401 P值 0.516a 0.683a 0.999a 0.620a 0.009a 0.011 0.001 0.691 注:a为采用Fisher精确检验。 表 3 2组PAU患者近期随访结果比较[例(%)]
组别 例数 血压控制不佳 冠心病 脑卒中 肾功能不全 溃疡增大 新发主动脉夹层 全因死亡 主动脉破裂死亡 其他原因死亡 保守治疗组 12 2(16.7) 0(0.0) 1(8.3) 0(0.0) 0(0.0) 3(25.0) 1(8.3) 1(8.3) 0(0.0) EVAR组 20 5(25.0) 0(0.0) 1(5.0) 2(10.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) P值 0.683 0.999 0.516 0.044 0.999 0.999 表 4 2组PAU患者远期随访结果比较[例(%)]
组别 例数 血压控制不佳 冠心病 脑卒中 肾功能不全 溃疡增大 新发主动脉夹层 全因死亡 主动脉破裂死亡 其他原因死亡 保守治疗组 9 1(11.1) 1(11.1) 1(11.1) 1(11.1) 2(22.2) 2(22.2) 3(33.3) 2(22.2) 1(11.1) EVAR组 20 3(15.0) 1(5.0) 1(5.0) 2(10.0) 0(0.0) 0(0.0) 2(10.0) 0(0.0) 2(10.0) P值 0.999 0.532 0.532 0.999 0.089 0.089 0.287 0.089 0.999 -
[1] LIU J, LIU Y, YANG W, et al. Five-year outcomes after thoracic endovascular aortic repair of symptomatic type B penetrating aortic ulcer with intramural hematoma in Chinese patients[J]. J Thorac Dis, 2019, 11(1): 206-213. doi: 10.21037/jtd.2018.12.86 [2] KOTSIS T, SPYROPOULOS B G, ASALOUMIDIS N, et al. Penetrating atherosclerotic ulcers of the abdominal aorta: a case report and review of the literature[J]. Vasc Specialist Int, 2019, 35(3): 152-159. doi: 10.5758/vsi.2019.35.3.152 [3] ODERICH G S, KÄRKKÄINEN J M, REED N R, et al. Penetrating aortic ulcer and intramural hematoma[J]. Cardiovasc Intert Rad, 2019, 42(3): 321-334. doi: 10.1007/s00270-018-2114-x [4] BERGER T, RYLSKI B, BEYERSDORF F, et al. Type B intramural hematoma and descending penetrating aortic ulcer[J]. Ann Cardiothorac Surg, 2019, 8(4): 488-489. doi: 10.21037/acs.2019.04.09 [5] STANSON A W, KAZMIER F J, HOLLIER L H, et al. Penetrating atherosclerotic ulcers of the thoracic aorta: natural history and clinicopathologic correlations[J]. Ann Vasc Surg, 1986, 1(1): 15-23. doi: 10.1016/S0890-5096(06)60697-3 [6] WADA H, SAKATA N, TASHIRO T. Clinicopathological study on penetrating atherosclerotic ulcers and aortic dissection: distinct pattern of development of initial event[J]. Heart Vessels, 2016, 31(11): 1855-1861. doi: 10.1007/s00380-016-0813-2 [7] DEMARTINO R R, SEN I, HUANG Y, et al. Population-based assessment of the incidence of aortic dissection, intramural hematoma, and penetrating ulcer, and its associated mortality from 1995 to 2015[J]. Circ Cardiovasc Qual, 2018, 11(8): e004689. http://www.zhangqiaokeyan.com/academic-journal-foreign-pmc_detail_thesis/040005238904.html [8] NATHAN D P, BOONN W, LAI E, et al. Presentation, complications, and natural history of penetrating atherosclerotic ulcer disease[J]. J Vasc Surg, 2012, 55(1): 10-15. doi: 10.1016/j.jvs.2011.08.005 [9] JÁNOSI R A, GORLA R, TSAGAKIS K, et al. Thoracic endovascular repair of complicated penetrating aortic ulcer: an 11-year single-center experience[J]. J Endovasc Ther, 2016, 23(1): 150-159. doi: 10.1177/1526602815613790 [10] EL HASSANI I, VAN DAMME H, CREEMERS E, et al. Penetrating atherosclerosis aortic ulcer: a re-appraisal[J]. Acta Chir Belg, 2017, 117(1): 1-7. doi: 10.1080/00015458.2016.1212566 [11] GIFFORD S M, DUNCAN A A, GREITEN L E, et al. The natural history and outcomes for thoracic and abdominal penetrating aortic ulcers[J]. J Vasc Surg, 2016, 63(5): 1182-1188. doi: 10.1016/j.jvs.2015.11.050 [12] 蒋小浪, 潘天岳, 董智慧, 等. 穿透性主动脉溃疡的干预时机与指征[J]. 中华普通外科杂志, 2020, 35(3): 264-266. doi: 10.3760/cma.j.cn113855-20190522-00275 [13] RIAMBAU V, BÖCKLER D, BRUNKWALL J, et al. Editor's choice-management of descending thoracic aorta diseases: clinical practice guidelines of the european society for vascular surgery (ESVS)[J]. Eur J Vasc Endovasc Surg, 2017, 53(1): 4-52. doi: 10.1016/j.ejvs.2016.06.005 [14] EVANGELISTA A, MALDONADO G, MORAL S, et al. Intramural hematoma and penetrating ulcer in the descending aorta: differences and similarities[J]. Ann Cardiothorac Surg, 2019, 8(4): 456-470. doi: 10.21037/acs.2019.07.05 [15] 李江, 黄剑, 赵建庭, 等. 急性症状性穿透性主动脉溃疡临床特点及治疗经验[J]. 中华血管外科杂志, 2017, 2(1): 50-53. [16] CHOU A S, ZIGANSHIN B A, CHARILAOU P, et al. Long-term behavior of aortic intramural hematomas and penetrating ulcers[J]. J Thorac Cardiovasc Surg, 2016, 151(2): 361-373. e1. doi: 10.1016/j.jtcvs.2015.09.012
计量
- 文章访问数: 600
- HTML全文浏览量: 120
- PDF下载量: 23
- 被引次数: 0